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Abstract   28 
Antibiotic-associated diarrhea (AAD) is associated with altered intestinal microflora and other 29 
symptoms that may lead to possibly death.  In critically ill patients, diarrhea increases rates of 30 
morbimortality.  Assessing diarrhea risks is thus important for clinicians.  For this reason, we 31 
conducted a hypothesis-generating study focused on antibiotic-associated diarrhea (AAD) to 32 
provide insight into methods of prevention.  We evaluated the hypothesis of predisposing 33 
factors within the resident intestinal microbiota in a cohort of outpatients receiving 34 
antibiotherapy.  Among the pool of tested variables, only those related to bacterial 16S rRNA 35 
genes were found to be relevant.  Complex statistical analyses provided further information: 36 
amid the bacteria 16S rRNA genes, eight were determined to be essential for diarrhea 37 
predisposition and characterized from the most important to the least.  Using these markers, 38 
AAD risk could be estimated with an error of 2%.  This molecular analysis offers new 39 
perspectives for clinical applications at the level of prevention.  40 
 41 
Key words:  Data-Mining/Diarrhea/Microbiota genes/Prevention/Risk factors 42 
 43 
 44 
 45 
 46 
 47 
 48 
 49 
 50 
 51 
 52 
 53 
 54 
 55 
 56 
 57 
 58 
 59 
 60 
 61 
 62 
 3 
Introduction  63 
The collective effects of the intestinal microbiota are dictated by a complex network of 64 
interactions that span the cellular, immunological, and environmental levels.  A primary 65 
question is whether a simple system can be applied to predict and control the effects of this 66 
heterogeneous population composed of different subgroups.  One approach in addressing this 67 
question is to study representative genes that correlate with the health consequences of the 68 
bacteria mixture comprising the microbiota.  The present study concerns specific bacterial 69 
populations associated with antibiotic-associated diarrhea (AAD).  This hypothesis-generating 70 
experiment was conducted to discern whether an analysis of bacterial 16S rRNA genes from 71 
pre-antibiotic resident faecal microbiota using with complex statistics could predict the 72 
collective effects of the intestinal microbiota, thereby identifying individual risk factors for 73 
diarrhea associated with antibiotic treatment. These specific gene sequences have been chosen 74 
because they have been the far most common genetic marker used (16). 75 
Antibiotic-associated diarrhea (AAD) is associated with altered intestinal microflora, 76 
mucosal integrity, vitamin, mineral metabolism and crampy abdominal pain. If severe, AAD 77 
may lead to electrolyte disturbances, dehydration, premature discontinuation of antibiotic 78 
therapy, pseudomembranous colitis, toxic megacolon and possibly death. Reports in the 79 
general population indicate that the incidence of AAD ranges from 25 to 62%, occurring at 80 
any point from the initiation of therapy to two months after the end of treatment (2, 17). In 81 
critically ill patients, diarrhea increases morbimortabilty.  AAD leads also to longer hospital 82 
stays and higher medical costs (1, 26, 27).  The pathogenesis of AAD may be mediated 83 
through the disruption of the normal microbiota and overgrowth of pathogens, or through 84 
metabolic imbalances (3, 31).  The individual risk for AAD varies greatly, influenced by host 85 
factors (age or diet), and type, dose, and duration of antibiotherapy (15, 22).  Assessment of 86 
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the diarrhea risk during antibiotic treatment is therefore worthwhile and may help control 87 
diarrhea in defined high-risk individuals; however, few data exist on risk factors for AAD. 88 
The role of the human intestinal microbiota in health and specific diseases is a 89 
particularly important area of research (7, 12, 13).  Substantial progress has recently been 90 
made in characterizing the human intestinal microbiota, although its role in immune system 91 
development and regulation, nutrition, and pathogenesis of the host are still not well 92 
elucidated (30).  Furthermore, the rapid rate of microbial evolution, combined with the global 93 
rise of antimicrobial resistance and the low rate of novel antibiotic development underscores 94 
the urgent need for innovative therapeutics (5, 10).  Culture-based techniques have 95 
traditionally been used to determine the faecal microbiota.  However, molecular techniques 96 
based on analysis of 16S rRNA genes directly amplified from bacterial DNA extracted from 97 
feces have estimated that less than 25% of the faecal bacterial populations have been cultured 98 
to date (11, 28).  These approaches have provided considerable data about microbial 99 
ecosystems, including that of the human gastrointestinal tract.  Detailed phylogenetic 100 
informations have been obtained by cloning and sequencing 16S rRNA genes.  Further, 101 
several studies with fingerprinting of 16S rRNA genes have reported its benefits in 102 
monitoring community shifts (8, 19, 23, 29).  103 
Hence, as a system model for the analysis of heterogeneous populations of bacteria, 104 
we analysed the 16S rRNA genes in the genomes of all bacteria using temporal temperature 105 
gradient gel electrophoresis (6), and multivariable data analysis (21).  In this retrospective 106 
study, we hypothesized that the susceptibility to diarrhea may be linked to the resident 107 
intestinal microbiota.  For this purpose we focused on a published clinical study (4), which 108 
included epidemiology forms, patient history, and laboratory reports; we analyzed database 109 
case records, specimen collection, and risk factors. We designed complex statistical analyses 110 
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to determine the optimal procedures for providing the maximum relevant information with 111 
fingerprint data, and obtaining knowledge about the 16S rRNA gene system.  112 
 113 
Methods 114 
Patients.  Subjects enrolled in this study were adults (age range, 20-60 years) living in 115 
the Paris area.  Subjects were prescribed a course of antimicrobial therapy for an ear, nose, or 116 
throat infection.  Criteria for enrollment included prescription by a general practitioner for a 117 
5-to 10-day course of antibiotics and age of 18 years or older.  Potential candidates were 118 
excluded if they were institutionalized, had received antibiotic treatment during the previous 2 119 
months, had been admitted to a hospital during the previous 6 months, had a known human 120 
immunodeficiency virus infection, had any allergy, or had experienced a bout of diarrhea (>2 121 
loose stools/day) the day before enrollment.  All patients provided informed written consent.  122 
Prescribed antibiotics were classified into one of the following groups: amoxicillin/clavulanic 123 
acid, other beta-lactam agents, or non-beta-lactam agents.  Diarrhea was defined as the 124 
passage of at least three loose stools a day, AAD was defined as diarrhea associated with the 125 
administration of antibiotics (in the absence of any other obvious reason) during the 14-day 126 
study period.  Each patient was asked to store the last stool before the beginning of the 127 
antibiotherapy (D0) in a double-thickness container.  The dominant microbiota profile at D0 128 
was considered to be patient’s profile at equilibrium (i.e., the resident microbiota).  In 129 
addition to the molecular study, bacteriological investigations were performed according to 130 
standardized procedures.  131 
DNA isolation and 16S rRNA gene amplification.  Immediately after faecal sample 132 
collection, total DNA was extracted from a 125-mg aliquot and purified as previously 133 
described (9). DNA (0.23 ± 0.1 µg/µl) was obtained from all samples.  The DNA integrity 134 
and concentration (size, >21kb) were determined by 1.5% agarose gel
 
electrophoresis with 135 
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ethidium bromide.  Isolated DNA was subsequently used as a template to amplify the V6 to 136 
V8 regions of the bacterial 16S rRNA gene with primers U968-GC and L1401 (32). 137 
Contamination and amplification controls were performed at each steps as previously 138 
described (9). 139 
TTGE analysis of PCR amplicons.  The Dcode universal mutation detection system 140 
(Bio-Rad, Paris, France) was used for sequence-specific separation of PCR products as 141 
previously described.  After electrophoresis, the gel was stained and analyzed using Quantity 142 
One software of the Gel Doc 2000 gel documentation system (Bio-Rad, Paris, France).  143 
TTGE gel analysis.  Each grey band of the TTGE gels was considered an amplicon of 144 
the 16S rRNA gene.  To simplify analysis, we used zones of the electrophoretic gels to 145 
describe the migration distances representing individual 16S rRNA genes.  TTGE profiles 146 
were compared by using Gel Compare II software (Applied-Maths, Sint-Martens–Latem, 147 
Belgium).  The analysis took into account the number of bands, their positions on the gel, and 148 
their intensities.  Gray intensities were then recorded along a densitogram, with each band 149 
given rise to a distinct peak.  Thus each electrophoresis pattern was represented by a curve 150 
defined as grey intensity = function (normalized migration distance). A marker consisting of a 151 
mixture of PCR amplicons (seven cloned 16S rRNA genes from different bacterial species) 152 
was used to normalize the profiles as previously described (9).  Similarity coefficients 153 
(Pearson correlation method) were calculated for each profile, yielding a similarity matrix.  A 154 
dendrogram was constructed from this matrix using the UPGMA algorithm (unweighted pair 155 
group method using arithmetic averages).  156 
Data collection.  The acquired data from all D0 electrophoresis gels were collected as 157 
147 retention times that resulted from digitizing each electrophoresis at equal distance 158 
intervals.  Each patient was also characterized by qualitative features related to age, sex, 159 
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therapy and the eventual presence of AAD.  The ages were recoded into seven classes (from 160 
ages 20-29 to 80-89).  AAD was represented by two groups (absence or presence). 161 
 162 
Multivariable data-analysis  163 
Two analyses of the data has been carried out in order to detect retentions times predictive of 164 
the AAD: ANOVA which compare the mean values at each retention times between the two 165 
groups, and discriminant analysis which allows to detect the more important retention times to 166 
predict AAD. 167 
Analysis of variances.  Each of the 147 retention times was explained by a four-way 168 
analysis of variance (ANOVA) including age, sex, therapy and AAD as independent 169 
variables. The aim of these analysis was to detect the retention times where there was 170 
significant differences between the two groups of patients (absence or presence of AAD), by 171 
adjusting the analysis on clinical variables (age, sex and therapy).   172 
In order to take into account the multiplicity of the tests, the F statistics associated to 173 
absence/presence of AAD of the ANOVA were compared to the value obtained with the 174 
following process: 10000 simulated datasets were generated by using the observed retention 175 
times and by simulating the factors age, sex, therapy and presence/absence of AAD with the 176 
same distributions than these ones observed in the sample independently of the retention 177 
times. The retained threshold for the F statistics (referenced as threshold F value) was the 178 
value of the F where 5% of the simulated datasets were above. This threshold corresponds to 179 
the 5% significant level obtained by chance. Only the retention times where the corresponding 180 
F values are above this threshold are retained as significantly predictive of the AAD. 181 
Discriminant analysis.  A discriminant analysis was carried out in order to detect 182 
retention times which allow predicting the AAD for the patients. Forward selection of the 183 
retention times was realized: At each step, the retention time which allows improving the 184 
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more the clustering of the patients in the two groups (correct clustering between 185 
absence/presence of AAD) is introduced in the analysis, until there is no more possible 186 
improvement of the clustering.  187 
 188 
 189 
Results 190 
Among the 156 patients included in the study, 44 developed an AAD.  None of the 44 191 
patients with diarrhea had stool culture positive for the tested intestinal pathogens Salmonella 192 
spp., Shigella spp., Campylobacter spp. and Yersinia spp.); however, six patients acquired 193 
Clostridium difficile.  194 
 TTGE gel analysis.  From DNA extracted from D0 stool samples (before 195 
antibiotherapy) 156 TTGE profiles were analyzed.  The banding pattern was complex in all 196 
cases (Figure 1), the number of bands ranged from 10 to 20.  The dendrogram analysis 197 
(unweighted pair group method with arithmetic mean (UPGMA) dendrogram not presented 198 
here) showed that the TTGE profiles did not cluster according to the onset of AAD. These 199 
results corroborate that, for each individual, microbial diversity and composition are specific 200 
traits (20). Thus, the need for extra complex analyses is pointed out in order to find any 201 
grouping within the microbiota profiles, before treatment. 202 
Multivariable data-analysis: Using multivariate data analysis techniques to determine 203 
potential causal factors for AAD, we found that only D0 microbiota profiles were strongly 204 
correlated with AAD.  In this study, other factors (age, sex, and class of antibiotic) were not 205 
relevant, thus we focused on the intestinal bacterial 16S rRNA genes: each TTGE profile was 206 
converted into a curve, then digitized and further analysed to convert 16S rRNA genes to 207 
numerical data (see complementary material). We applied advanced multivariate analysis to 208 
confirm any predictive signature of the intestinal microbiota.  209 
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Variance analysis. Figure 2 shows the F- value of ANOVA carried out independently at each 210 
data point of each electrophoresis at D0.  The studied factor was the presence/absence of AAD 211 
after antibiotherapy.  Six electrophoresis migration distance values were found exceed the 212 
threshold F-value: (A) 58, (B) 70, (C) 174, (D) 321, (E) 358 and (F) 399.  Figure 3 shows the 213 
mean electrophoresis migration patterns associated with the absence and presence of AAD: 214 
significant regions are emphasized using a grey color. Zones A and F are correlated to the 215 
microbiota of patients with AAD, and zones B, C, D, and E are correlated to the microbiota of 216 
patients without AAD.  217 
Discriminant analysis. Six retention times explaining the absence/presence of AAD have 218 
been selected by the forward selection of the variables for the discriminant analysis (FLDA). 219 
These 6 variables allow clustering 142 among the 156 patients (91%) in the correct group. 220 
 221 
Individual risk prediction of AAD from resident intestinal microbiota. Figure 4 222 
demonstrates the degree of agreement between ANOVA and FLDA.  Four of the first six 223 
variables selected by the discriminant analysis were also identified by ANOVA, producing 224 
distinct profiles for AAD and no AAD.  The risk prediction for any new case of AAD could 225 
be calculated from its intestinal microbiota gene fingerprinting with an error of 2% in the case 226 
of AAD (1/44) and 11% (12/112) in the case of no AAD. 227 
 228 
Discussion  229 
Predicting and controlling the effects of a heterogeneous bacteria population is a 230 
highly challenging task with many biological and clinical applications.  To study this 231 
question, we evaluated relationships between intestinal bacterial 16S rRNA genes and AAD, 232 
which is a growing health concern.  Why some patients develop AAD while others do not is a 233 
recurrent and unresolved question.  This paper describes for the first time a computational 234 
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approach that accurately predicts the relationship between the resident microbiota and the risk 235 
for developing AAD.  236 
 237 
The important findings of this study are as follows:  238 
i.) Among the studied patient variables (antibiotherapy, age, sex, bacterial 16S rRNA 239 
genes), only the pre-antibiotic resident faecal bacterial 16S rRNA genes were found to be 240 
correlated to AAD. 241 
ii.) Among the bacterial 16S rRNA genes studied, one group was found to be crucial for 242 
the predisposition for AAD.  This group is composed of eight specific electrophoretic 243 
distances, thus eight specific set of genes, classified from most important to least important: 244 
all eight were required for the development of diarrhea.  245 
iii.) Risk factors could be calculated; AAD could be predicted from the resident intestinal 246 
bacterial 16S rRNA gene analysis with an error of 2%, and no AAD with an error of 11%. 247 
 248 
These observations are based on the investigation of the dominant faecal bacterial 249 
populations before any antibiotherapy, by fingerprinting techniques applied to samples from a 250 
cohort of outpatients treated by antibiotherapy for ear, nose and throat infections (non 251 
invasive sampling).  Those conclusions are valid within the context of the study, but do not 252 
account for variation outside the dataset.  253 
The strengths of this study include the uniqueness of this type of analysis on bacterial 254 
genes from the resident faecal microbiota.  It is based on a comprehensive causal model that 255 
describes the relationships among numerous risk factors for AAD.  The weakness of this 256 
study is the lack of phylogenetic analysis; the study does not provide information regarding 257 
the specific microorganisms involved in AAD risk.  Our aim was to determine the presence of 258 
risk factors for AAD among the 16S rRNA genes. The 16S rRNA gene is an ~1500 base pair 259 
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gene that codes for a portion of the 30S ribosome. Partial (500-base pair) 16S rRNA gene 260 
sequencing has emerged as an accurate method to identify a wide variety of bacteria and has 261 
been successfully implemented in clinical laboratories (24, 25). A major limitation of the 16S 262 
rRNA gene sequencing, though, is its inability to discriminate among all bacterial taxa. In that 263 
case alternative gene targets can provide better separation of closely related species (e.g. rpoB 264 
gene) (18) . However, in this work, the aim was not to identify bacteria, although it looks 265 
rather frustrating not to. Ultimately, the goal is to associate differences in communities with 266 
differences in metabolic function and/or disease (AAD).  Thus these work and the results 267 
explain here, stand as one first step toward it.  Therefore, the findings of this study are being 268 
used for further work on the impact of the resident microbiota. Then, in-depth phylogenetic 269 
analysis of the microbiota will be needed and preventing strategies developed.  270 
We started with the assumption of a predictive signature of the microbiota. The 271 
statistical analysis shows significant differences in the migration patterns between the two 272 
groups (absence/presence of AAD). Moreover, this analysis shows that the AAD can be 273 
correctly predicted with data based exclusively on migration distances. As a consequence, it 274 
can be conclude that the nature of the microbiota before antibiotherapy may play a role in 275 
AAD. 276 
The variance analysis identified six significant zones (A to F); the discriminant 277 
analysis also identified six significant regions (1 to 6) in order of decreasing importance, all of 278 
which are required for prediction.  Interestingly, only four zones were common between the 279 
two analyses (B to 4, C to 2, E to 6 and F to 1).  Further, if an intestinal microbiota 16S rRNA 280 
gene profile shows the six zones indicating no AAD and does not show the two zones 281 
indicating AAD, it can be assumed that the patient is not likely to develop AAD.  One 282 
potentially confusing aspect of this study is that we speak of numerical data, so we describe 283 
risk in terms of “zones”, that is to say, electrophoretic distances representing the16S rRNA 284 
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genes.  The next area of study will be to determine to which extend they are associated to 285 
phylogenetic species. 286 
Fingerprinting techniques such as TTGE are powerful analysis tools for detecting 287 
biomedically relevant markers such as nucleic acids and proteins and ultimately diseases or 288 
disease progression that can alter the structure of biological systems like intestinal microbiota. 289 
Multivariate data-analysis techniques are essential to manipulate and interpret these enormous 290 
amounts of data, and appropriately address the inherent complexity of data derived from 291 
biomedical samples.  In addition, different multivariate algorithms must be tested to 292 
determine the most suitable method(s) for establishing reliable, robust, and accurate 293 
classification or regression models, while minimizing false-positive and false-negative results.  294 
Nonetheless, multivariate data-analysis techniques should be used cautiously, as a 295 
complement to optimized diagnostic techniques that already provide relevant information.  296 
Specifically, useful information obtained by fingerprinting techniques like TTGE (i.e., 297 
bacterial diversity) increases with a priori knowledge of the samples and the individual (age 298 
group, treatment), which enhances the accuracy and reliability of classification and regression 299 
techniques based on pattern recognition.  It is noteworthy that our study, neither age groups 300 
nor antibiotic treatments were important indicators of AAD.   301 
 In conclusion, we are aware of the limitations of relatively small number of patients 302 
used in this study, the complex structure of the data, and the need for verification of our 303 
findings.  The broad application spectrum of sequence-dependent fingerprinting techniques in 304 
the field of intestinal microbiology has been largely examined. It ranges from primary 305 
assessments of the bacterial complexity and diversity of intestinal community structures to the 306 
monitoring of compositional changes at different population levels upon dietary or therapeutic 307 
intervention (14) . In this model, causal modeling was based on current TTGE gel analysis 308 
and thus has the same limitations of any genetic analysis using biomolecular engineering (e. 309 
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g. DNA extraction, amplification).  Therefore, it is possible that not all possible confounders 310 
are represented in the models, and some factors that are designated as no confounders might 311 
actually be so.  Additional population-based studies with multivariable analyses structured on 312 
causal models are required to confirm the findings of this study.  In addition, this study was 313 
primarily a hypothesis-generating study of resident microbiota genes, which utilized ever-314 
improving molecular techniques and analyses, and demonstrates that important part of risk 315 
factors for AAD can be found within the individual microbiome.  As such, it offers new 316 
perspectives for clinical applications at the level of prevention.  317 
 318 
 319 
 320 
 321 
 322 
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Figure legends 452 
Figure.1. Representative TTGE gel image of faecal microbiota DNA before antibiotic 453 
treatment.  M control marker DNA. 454 
Figure.2.  Analysis of Variance (ANOVA).  Fisher F-values (AAD) are plotted against the 455 
migration distance.  The Fisher F limit (threshold value) was obtained using randomisation 456 
procedures (see Methods).  Six electrophoresis distances were found to exceed this threshold, 457 
and were thus considered significant.  458 
Figure.3. Mean TTGE electrophoresis at D0.  The grey bars emphasize the regions detected 459 
by ANOVA tests.  Solid line, pattern from patients with AAD; Dotted line, pattern from 460 
patients without ADD.  461 
Figure.4. Comparison of ANOVA and discriminant analysis.  Top : regions detected by 462 
ANOVA (grey bars) Bottom: first six variables introduced in forward discriminant analysis 463 
(vertical lines). Vertical lines are numbered in order of introduction of the corresponding 464 
variable. Solid line, pattern from patients with AAD; Dotted line, pattern from patients 465 
without AAD.  466 
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